Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| TREVENA INC | 64,103 | reported | 13 May 2020 | tx 44+2,914,079−847,892 |
| Akebia Therapeutics, Inc. | 24,133 | reported | 08 Jun 2020 | tx 11+121,400−4,567 |
| Aclaris Therapeutics, Inc. | 21,754 | reported | 06 Jun 2025 | tx 23+189,438−21,754 |
| SANTARUS INC | 20,000 | reported | 06 Apr 2004 | tx 5+1,207,656−3,981,842 |
| Passage BIO, Inc. | 10,539 | reported | 19 May 2026 | tx 8+386,467 |
| IDERA PHARMACEUTICALS, INC. | 0 | reported | 10 Aug 2023 | tx 13+308,085−51 |
| Merus N.V. | 0 | reported | 12 Dec 2025 | tx 12+77,535−73,252 |
| HUMAN GENOME SCIENCES INC | 0 | reported | 30 Jul 2012 | tx 24+141,589.14−109,589.14 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 19 May 2026 | GRANT_AWARD | Passage BIO, Inc. | 10,539 | 0.00 USD | deriv |
| 12 Dec 2025 | OTHER | Merus N.V. | 13,193 | 0.00 USD | deriv |
| 12 Dec 2025 | OTHER | Merus N.V. | 8,844 | 0.00 USD | deriv |
| 12 Dec 2025 | OTHER | Merus N.V. | 7,957 | 0.00 USD | deriv |
| 12 Dec 2025 | OTHER | Merus N.V. | 16,604 | 0.00 USD | deriv |
| 12 Dec 2025 | OTHER | Merus N.V. | 12,240 | 0.00 USD | deriv |
| 12 Dec 2025 | OTHER | Merus N.V. | 14,414 | 0.00 USD | deriv |
| 06 Jun 2025 | EXERCISE | Aclaris Therapeutics, Inc. | 4,793 | — | |
| 05 Jun 2025 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 42,350 | 0.00 USD | deriv |
| 05 Jun 2025 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 11,580 | 0.00 USD | deriv |
| 06 Jun 2025 | EXERCISE | Aclaris Therapeutics, Inc. | 4,793 | 0.00 USD | deriv |
| 28 May 2025 | GRANT_AWARD | Passage BIO, Inc. | 201,857 | 0.00 USD | deriv |
| 22 May 2025 | GRANT_AWARD | Merus N.V. | 13,193 | 0.00 USD | deriv |
| 06 Jun 2024 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 4,793 | 0.00 USD | deriv |
| 06 Jun 2024 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 15,750 | 0.00 USD | deriv |
| 01 Jun 2024 | EXERCISE | Aclaris Therapeutics, Inc. | 4,660 | — | |
| 01 Jun 2024 | EXERCISE | Aclaris Therapeutics, Inc. | 4,660 | 0.00 USD | deriv |
| 21 May 2024 | GRANT_AWARD | Passage BIO, Inc. | 47,693 | 0.00 USD | deriv |
| 07 May 2024 | GRANT_AWARD | Merus N.V. | 8,844 | 0.00 USD | deriv |
| 10 Aug 2023 | SALE | IDERA PHARMACEUTICALS, INC. | 51 | 0.51 USD | |
| 08 Jun 2023 | GRANT_AWARD | Merus N.V. | 14,414 | 0.00 USD | deriv |
| 02 Jun 2023 | EXERCISE | Aclaris Therapeutics, Inc. | 4,507 | — | |
| 01 Jun 2023 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 4,660 | 0.00 USD | deriv |
| 01 Jun 2023 | GRANT_AWARD | Aclaris Therapeutics, Inc. | 15,750 | 0.00 USD | deriv |
| 02 Jun 2023 | EXERCISE | Aclaris Therapeutics, Inc. | 4,507 | 0.00 USD | deriv |
3 purchases reported after at least 12 months of silence — most recent on 01 Feb 2019.